Industry News
Biotechnology Industry News
Twelve years after establishing…
Twelve years after establishing TechBio company Recursion, co-founder and CEO Chris Gibson, Ph.D., will soon step down to let Chief R&D and Commercial Officer Najat Khan, Ph.D., take the wheel.
Biotech firm prepares for pivotal…
Biotech firm prepares for pivotal trials as it positions Teverelix to address unmet needs in prostate cancer, urology and beyond.
The FDA has released the second…
The FDA has released the second batch of recipients for the new "national priority voucher" program, with executives for two of the beneficiaries appearing in the Oval Office with President Donald Trump Nov. 6.
More than a year and a half into…
More than a year and a half into Cullinan Therapeutics’ pivot from a CD19-focused oncology company to a hybrid autoimmune player, the biotech is parting ways with a pair of cancer programs.
Discover how these trailblazers…
Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews below to get inspired and stay ahead of the curve.
Axsome Therapeutics has wrapped…
Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue Therapeutics' subsidiary Baergic Bio, in a deal potentially worth more than $83 million.
UroGen is handing an anti-CTLA-4…
UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding that phase 1 data for the bladder cancer drug didn’t reach the benchmark for further development.
First, the phase 3 trial of…
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough
Eli Lilly has linked its amylin…
Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month.
Evommune is heading to the New…
Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO that the inflammation biotech will use to fund a pair of clinical-stage candidates.
AstraZeneca has ended work on one…
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
Dynavax is paying $30 million…
Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the program.
Amid the rapidly unfolding saga…
Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout bid for the biotech, Bloomberg reports.
In a letter to lawyers for Novo…
In a letter to lawyers for Novo and Metsera, an FTC official wrote that the proposed purchase of Metsera by the Danish pharma "may violate the procedural provisions" of the Hart-Scott-Rodino (HSR) Act.
Eli Lilly is inking a $100…
Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using AI to discover new drugs.
Novo Nordisk is winding down a…
Novo Nordisk is winding down a range of early-stage programs for liver disease, oncology and stem cells as part of the Danish Pharma’s ambitious restructuring.
Eli Lilly has pulled out of the…
Eli Lilly has pulled out of the central-nervous-system-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 inhibitors.
Novo Nordisk’s CEO won’t…
Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera but said the Big Pharma “feels this deal will be closed.
The FDA has rejected Biohaven’s…
The FDA has rejected Biohaven’s request for approval of a neurological disorder therapy, prompting the biopharma to reprioritize its pipeline.
Following a middling phase 3…
Following a middling phase 3 readout for gastric cancer candidate bemarituzumab, Amgen has stopped another trial of the molecule.